About Sutro Biopharma
Sutro Biopharma is a company based in United States founded in 2003.. Sutro Biopharma has raised $171.85 million across 11 funding rounds from investors including Merck, Citadel and Celgene. The company has 338 employees as of December 31, 2024. Sutro Biopharma offers products and services including XpressCF+ and iADCs. Sutro Biopharma operates in a competitive market with competitors including Moderna, Jazz Pharmaceuticals, BeiGene, Advanced Accelerator Applications and Incyte, among others.
- Headquarter United States
- Employees 338 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Sutro Biopharma, Inc.
-
Annual Revenue
$62.04 M-59.64as on Dec 31, 2024
-
Net Profit
$-227.46 M-112.99as on Dec 31, 2024
-
EBITDA
$-231.24 M-180.41as on Dec 31, 2024
-
Total Equity Funding
$171.85 M (USD)
in 11 rounds
-
Latest Funding Round
$85.4 M (USD), Series E
Jul 26, 2018
-
Investors
Merck
& 13 more
-
Employee Count
338
as on Dec 31, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Sutro Biopharma
Sutro Biopharma is a publicly listed company on the NASDAQ with ticker symbol STRO in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Sutro Biopharma
Sutro Biopharma offers a comprehensive portfolio of products and services, including XpressCF+ and iADCs. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Cell-free technology for protein expression in drug development.
Antibody-drug conjugates for targeted cancer treatments.
Unlock access to complete
Unlock access to complete
Leadership Team
43 people
Software Development Team
22 people
Senior Team
14 people
Product Management Team
10 people
Clinical Team
8 people
Scientist Team
8 people
Operations Team
5 people
Finance and Accounting
4 people
Unlock access to complete
Funding Insights of Sutro Biopharma
Sutro Biopharma has successfully raised a total of $171.85M across 11 strategic funding rounds. The most recent funding activity was a Series E round of $85.4 million completed in July 2018. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 11
- Last Round Series E — $85.4M
-
First Round
First Round
(01 Sep 2005)
- Investors Count 14
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2018 | Amount | Series E - Sutro Biopharma | Valuation | Samsara BioCapital , Citadel | |
| Dec, 2013 | Amount | Series D - Sutro Biopharma | Valuation | Alta Partners , Skyline Ventures | |
| May, 2012 | Amount | Series C - Sutro Biopharma | Valuation | Skyline Ventures |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Sutro Biopharma
Sutro Biopharma has secured backing from 14 investors, including venture fund and institutional investors. Prominent investors backing the company include Merck, Citadel and Celgene. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital funding is provided by Samsara BioCapital in California.
|
Founded Year | Domain | Location | |
|
Venture capital firm focused on healthcare companies
|
Founded Year | Domain | Location | |
|
Venture capital investments are facilitated by Amgen-backed entity.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Sutro Biopharma
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Sutro Biopharma
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Sutro Biopharma Comparisons
Competitors of Sutro Biopharma
Sutro Biopharma operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Moderna, Jazz Pharmaceuticals, BeiGene, Advanced Accelerator Applications and Incyte, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
mRNA-based therapeutics for diseases including cancer and infections are developed.
|
|
| domain | founded_year | HQ Location |
Novel biopharmaceutical medicines are developed for unmet medical needs.
|
|
| domain | founded_year | HQ Location |
Targeted and immune-oncology drugs for cancer treatment are developed.
|
|
| domain | founded_year | HQ Location |
Radiopharmaceuticals for oncology diagnostics and therapies are developed and marketed.
|
|
| domain | founded_year | HQ Location |
Small molecules are developed for cancer and skin disease treatments.
|
|
| domain | founded_year | HQ Location |
Cancer therapies are developed using selective pathway inhibitors.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Sutro Biopharma
Frequently Asked Questions about Sutro Biopharma
When was Sutro Biopharma founded?
Sutro Biopharma was founded in 2003 and raised its 1st funding round 2 years after it was founded.
Where is Sutro Biopharma located?
Sutro Biopharma is headquartered in United States.
Is Sutro Biopharma a funded company?
Sutro Biopharma is a funded company, having raised a total of $171.85M across 11 funding rounds to date. The company's 1st funding round was a Series C of $16.5M, raised on Sep 01, 2005.
How many employees does Sutro Biopharma have?
As of Dec 31, 2024, the latest employee count at Sutro Biopharma is 338.
What is the annual revenue of Sutro Biopharma?
Annual revenue of Sutro Biopharma is $62.04M as on Dec 31, 2024.
What does Sutro Biopharma do?
Sutro Biopharma was founded in 2003 in the United States within the biotechnology sector. Antibody-based therapeutics targeting cancer are developed using the XpressCF cell-free protein synthesis platform. Discoveries such as STRO-001 for B-cell malignancies and STRO-002 for ovarian and endometrial cancers have been enabled by this technology. Operations focus on advancing these treatments through research and development in oncology.
Who are the top competitors of Sutro Biopharma?
Sutro Biopharma's top competitors include Moderna, Jazz Pharmaceuticals and Advanced Accelerator Applications.
What products or services does Sutro Biopharma offer?
Sutro Biopharma offers XpressCF+ and iADCs.
Is Sutro Biopharma publicly traded?
Yes, Sutro Biopharma is publicly traded on NASDAQ under the ticker symbol STRO.
Who are Sutro Biopharma's investors?
Sutro Biopharma has 14 investors. Key investors include Merck, Citadel, Celgene, Tekla Capital Management, and Samsara BioCapital.
What is Sutro Biopharma's ticker symbol?
The ticker symbol of Sutro Biopharma is STRO on NASDAQ.
Book a demo & talk to our team
Share a few details and we’ll reach out to schedule a session.